J&J CEO’s Recognition Questioned Due to Marketing of Risperdal

Home » Drug Injury » J&J CEO’s Recognition Questioned Due to Marketing of Risperdal

The CEO of Johnson & Johnson is set to receive a recommendation and honor from Jefferson Health. The Award of Merit dinner is held every fall to honor successful business people who make donations to Jefferson Health.

This November 28, Johnson & Johnson CEO Alex Gorsky is set to receive recognition. However, critics claim that his deception and decisions regarding the marketing of Risperdal should exclude him from receiving such an honor.

Marketing of Risperdal as a popular antipsychotic has led some patients and doctors to initiate concerns about the dangers behind the drug, particularly as it relates to young men developing gynecomastia.

A 2015 report reviews Gorsky’s oversight of the marketing of Risperdal. In the early 2000s, Risperdal’s sales topped $3 billion per year. In 2013, Johnson & Johnson agreed to pay more than $2 billion to settle criminal and civil charges with 45 states and the Justice Department.

Accordingly, the Justice Department said that Johnson & Johnson in its marketing of Risperdal encouraged that and two other drugs for uses that were not approved as safe by the Food and Drug Administration.

The marketing of Risperdal included recommendations for doctors to prescribe it to dementia patients and autistic children in a kickback scheme for pharmacy officials and doctors. Critics in the health care industry believe Gorsky should not be recognized for any specific honors because it was his responsibility to create and implement the marketing of Risperdal.

Legal Claims Filed Due to Marketing of Risperdal

The most recent lawsuit associated with Risperdal dangers led to a $70 million award against Johnson & Johnson for pushing Risperdal in an unapproved manner on boys whose families claimed that the patients developed gynecomastia. That decision is currently under appeal. The annual report for Johnson & Johnson in the last year included 13 pages of product liability lawsuits in government investigations.

Risperdal breast growth leads to depressionWhen drug companies develop a new prescription or tool, they must thoroughly test it in order to identify potential complications and side effects. Once these are discovered, the company may redevelop the drug or include concerns on a warning label.

If serious injuries or side effects are possible and the company knows about it and fails to warn patients, those affected by these medical concerns may choose to file a lawsuit.

Many patients have filed lawsuits due to the marketing of Risperdal. Those claims allege that the makers knew about the risk for gynecomastia and other problems and yet patients were never informed about the dangers. These allegations and other concerns about Risperdal side effects can prompt defective drug lawsuits.

If you or someone you know has been seriously injured due to taking Risperdal or has developed complicated side effects, you may be eligible to pursue a product liability claim with the help of experienced attorneys.

The lawyers at McDonald Worley represent patients who have developed severe Risperdal side effects. Fill out the form on this page to receive a free case evaluation.